Skip to main content
Top
Published in: Medical Oncology 2/2011

01-06-2011

Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549

Authors: Fang Zhu, Zhe Zhang, Gang Wu, Zhenyu Li, Ruiguang Zhang, Jinghua Ren, Li Nong

Published in: Medical Oncology | Issue 2/2011

Login to get access

Abstract

Rho and Rho-associated kinase play an important role in focal adhesion, stress fiber formation and cell motility. Fasudil is a kind of Rho kinase inhibitor. The effect and precise molecular mechanism of fasudil on the biology behavior of lung cancer cell A549 remains unclear. The cytotoxic effect of fasudil on A549 cell was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Wound-healing assay was used to evaluate the effect of fasudil on migration activity of A549 cells. The invasion activity of A549 cells was detected by transwell chamber assay. The expression of MMPs was measured by gelatin zymography. RT-PCR and western blot were used to investigate the molecular change of A549 cells after treated with fasudil. Fasudil-inhibited proliferation of A549 cells in a concentration-dependent manner, decreased the migration and invasion activity. After treated with fasudil, the expression of MMP-2 and MMP-9 was significantly inhibited compared with the control group. Furthermore, the expression of RhoA and VEGF of A549 cell treated with fasudil was significantly down-regulated. Our findings indicate that fasudil might have a therapeutic potential for lung cancer though inhibiting cell proliferation, migration, invasion, MMPs activity and down-regulating the expression of RhoA and VEGF.
Literature
1.
go back to reference Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15–36.PubMedCrossRef Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15–36.PubMedCrossRef
3.
go back to reference Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87:635–44.PubMedCrossRef Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87:635–44.PubMedCrossRef
4.
go back to reference Kamai T, Tsujii T, Arai K, Takagi K, Asami H, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632–41.PubMed Kamai T, Tsujii T, Arai K, Takagi K, Asami H, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632–41.PubMed
5.
go back to reference Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009;29:119–23.PubMed Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009;29:119–23.PubMed
6.
go back to reference Kamai T, Arai K, Tsujii T, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int. 2001;87:227–31.PubMedCrossRef Kamai T, Arai K, Tsujii T, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int. 2001;87:227–31.PubMedCrossRef
7.
go back to reference Wang HB, Liu XP, Liang J, Yang K, Sui AH, et al. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters. Clin Chem Lab Med. 2009;47:811–7.PubMedCrossRef Wang HB, Liu XP, Liang J, Yang K, Sui AH, et al. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters. Clin Chem Lab Med. 2009;47:811–7.PubMedCrossRef
8.
go back to reference Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer. 1999;81:682–7.PubMedCrossRef Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer. 1999;81:682–7.PubMedCrossRef
9.
go back to reference Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225–32.PubMedCrossRef Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225–32.PubMedCrossRef
10.
go back to reference Yang X, Liu Y, Zong Z, Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother. 2010;64:58–62.PubMedCrossRef Yang X, Liu Y, Zong Z, Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother. 2010;64:58–62.PubMedCrossRef
11.
go back to reference Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther. 2007;6:1517–25.PubMedCrossRef Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther. 2007;6:1517–25.PubMedCrossRef
12.
go back to reference Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–51.PubMedCrossRef Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–51.PubMedCrossRef
13.
go back to reference Lochter A, Bissell MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS. 1999;107:128–36.PubMedCrossRef Lochter A, Bissell MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS. 1999;107:128–36.PubMedCrossRef
14.
go back to reference Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49:7–19.PubMed Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49:7–19.PubMed
15.
go back to reference Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer. 1998;79:96–101.PubMedCrossRef Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer. 1998;79:96–101.PubMedCrossRef
16.
go back to reference Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395–9.PubMed Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395–9.PubMed
17.
18.
go back to reference Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2005;50(1):51–8.PubMedCrossRef Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2005;50(1):51–8.PubMedCrossRef
19.
20.
go back to reference Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.PubMedCrossRef Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.PubMedCrossRef
21.
go back to reference Rousseau S, Houle F, Landry J, Huot J. p38MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169–77.PubMedCrossRef Rousseau S, Houle F, Landry J, Huot J. p38MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169–77.PubMedCrossRef
22.
go back to reference Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277:36288–95.PubMedCrossRef Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277:36288–95.PubMedCrossRef
23.
go back to reference Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999;141:13–9.CrossRef Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999;141:13–9.CrossRef
24.
go back to reference Ralph MV, Bernard C, Deborah K, William BS, Steven G, et al. Efficacy and safety of fasudil in patients with stable angina: a double-bind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–11.CrossRef Ralph MV, Bernard C, Deborah K, William BS, Steven G, et al. Efficacy and safety of fasudil in patients with stable angina: a double-bind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–11.CrossRef
Metadata
Title
Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549
Authors
Fang Zhu
Zhe Zhang
Gang Wu
Zhenyu Li
Ruiguang Zhang
Jinghua Ren
Li Nong
Publication date
01-06-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9468-5

Other articles of this Issue 2/2011

Medical Oncology 2/2011 Go to the issue